Merus nimmt an Kamingespräch auf der RBC Capital Markets Global Healthcare Conference 2021 teil
May 11, 2021 14:29 ET
|
Merus N.V.
UTRECHT, Niederlande, und CAMBRIDGE, Mass., USA, May 11, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), ein Unternehmen aus dem Bereich der klinischen Onkologie, das innovative multispezifische...
Merus to Participate in a Fireside Chat at the 2021 RBC Capital Markets Global Healthcare Conference
May 11, 2021 08:00 ET
|
Merus N.V.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 11, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific...
Merus Announces Financial Results for the First Quarter and Provides Business Update
May 06, 2021 17:14 ET
|
Merus N.V.
Clinical data update on zenocutuzumab selected for oral presentation at ASCO MCLA-145 clinical update planned for 2H21 MCLA-129 first patient dosed in phase 1/2 trial Cecile Geuijen, Ph.D., promoted...
Merus Announces First Patient Treated in Phase 1/2 Clinical Trial of MCLA-129 in Advanced Lung Cancer and Other Solid Tumors
May 03, 2021 16:01 ET
|
Merus N.V.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 03, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing...
Zenocutuzumab Clinical Data Selected for Oral Presentation at the 2021 American Society of Clinical Oncology Annual Meeting
April 28, 2021 16:01 ET
|
Merus N.V.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing...
Merus Announces Financial Results for the Fourth Quarter and Full Year 2020 and Provides Business Update
March 16, 2021 16:57 ET
|
Merus N.V.
Clinical data and program update planned for lead program zenocutuzumab (“Zeno”) in 2Q 2021 Clinical update planned for MCLA-145 in 2H 2021 MCLA-129 expected to enter clinic in the United States in...
Merus Announces Poster Presentations for Zenocutuzumab and MCLA-129 at the American Association for Cancer Research 2021 Annual Meeting
March 10, 2021 16:45 ET
|
Merus N.V.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing...
Merus to Participate in a Fireside Chat at the 33rd Annual Roth Conference
March 08, 2021 08:00 ET
|
Merus N.V.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., March 08, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific...
Merus Announces Pricing of Public Offering of Common Shares
January 21, 2021 08:41 ET
|
Merus N.V.
UTRECHT, The Netherlands, and CAMBRIDGE, Mass., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we” and “our”), a clinical-stage oncology company developing innovative,...
Merus N.V. Announces Proposed Public Offering of Common Shares
January 19, 2021 16:18 ET
|
Merus N.V.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we” and “our”), a clinical-stage oncology company developing innovative,...